May 11, 2023
The U.S. Drug Enforcement Administration (DEA) is extending the ability for physicians to prescribe controlled substances based on telehealth visits through November 11, 2023. This method had been set to expire when the COVID-19 Public Health Emergency ended today (May 11).
On March 1, the DEA and the Department of Health and Human Services (HHS), sent out notices of proposed rulemakings (NPRMs) to generate feedback on proposals to continue allowing the prescribing of controlled medications via virtual visits with patients. More than 38,000 public comments came in.
“These medications, including those used to treat opioid use disorder, are a vital form of care for millions of Americans who have come to rely on safe and effective telemedicine appointments,” said the AMA in a statement. “Patients being treated with these medications often have challenges securing and traveling to in-person appointments.”
April 9, 2026
An amended piece of legislation that would exempt buprenorphine from prior authorization (PA) was heard in the Senate Health and Human Services Committee on April 9.
April 9, 2026
On April 9, the Senate Health and Human Services Committee heard a bill that would require coverage for psychiatric Collaborative Care Model (CoCM) services under Medical Assistance.
April 9, 2026
On April 9, the House Taxes Committee heard legislation focused on supporting the financial stability and ongoing operations of Hennepin Healthcare.